About this Research Topic
Epstein-Barr virus (EBV) is the first human tumor virus identified in 1964 in a Burkitt lymphoma. Later, the virus was found to be associated with other types of lymphomas (Hodgkin lymphoma and NK/T cells lymphoma) and carcinomas (nasopharyngeal carcinomas and a subset of gastric cancer). Primary infection usually occurs during infancy in the general population of developing countries but may be delayed in young adults in more industrialized regions. After infection, the virus persists in the memory B cells of the peripheral blood in a latent state with only a few viral products expressed. Periodically, the virus enters in the lytic phase, which is characterized by the expression of all virus genes and leads to the production of new infectious virions.
EBV infects over 95% of the adult human population worldwide and accounts for 200,000 new cancer cases and over 142,000 deaths worldwide every year. Understanding the strategies employed by EBV to escape the host immune system will lead to a better understanding of EBV-associated diseases.
To advance the understanding of strategies employed by EBV to escape immune response. In this special issue we welcome the submission of original research, case reports, reviews, and perspective articles describing and dissecting various mechanisms used by EBV to evade the immune response. This includes studies on how EBV minimizes the expression of viral proteins and uses diverse classes of molecules to limit viral detection and to escape from antiviral immunity.
Manuscripts consisting only of bioinformatics or computational analysis of publicly available databases need to be further accompanied by mechanistic and/or validation studies to be in the scope of the topic.
Topic Editor Rita Khoueiry is identified as personnel of the International Agency for Research on Cancer/World Health Organization, she is responsible for her views and contribution and she does not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
EBV infects over 95% of the adult human population worldwide and accounts for 200,000 new cancer cases and over 142,000 deaths worldwide every year. Understanding the strategies employed by EBV to escape the host immune system will lead to a better understanding of EBV-associated diseases.
To advance the understanding of strategies employed by EBV to escape immune response. In this special issue we welcome the submission of original research, case reports, reviews, and perspective articles describing and dissecting various mechanisms used by EBV to evade the immune response. This includes studies on how EBV minimizes the expression of viral proteins and uses diverse classes of molecules to limit viral detection and to escape from antiviral immunity.
Manuscripts consisting only of bioinformatics or computational analysis of publicly available databases need to be further accompanied by mechanistic and/or validation studies to be in the scope of the topic.
Topic Editor Rita Khoueiry is identified as personnel of the International Agency for Research on Cancer/World Health Organization, she is responsible for her views and contribution and she does not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: Epstein-Barr virus (EBV), immune escape/evasion, B cell, T cell, NK cells, antiviral response
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
